Our data demonstrate that setmelanotide reactivates PVN MC4R signaling, suppresses appetite, and reverses metabolic pathology in HO, providing mechanistic insight and highlighting the urgent need for innovative therapies for CNS-related obesity. Here, MC4R is linked to obesity disorder.